Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: SIX Swiss Ex
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Cosmo Pharmaceuticals SA

+ Add to Watchlist

COPN:SW

157.70 CHF 0.40 0.25%

As of 11:33:25 ET on 04/30/2015.

Snapshot for Cosmo Pharmaceuticals SA (COPN)

Open: 157.10 Day's Range: 154.10 - 159.00 Volume: 10,691
Previous Close: 158.10 52wk Range: 114.00 - 193.70 1-Yr Rtn: +34.79%

Stock Chart for COPN

No chart data available.
  • COPN:SW 157.70
  • 1D
  • 1M
  • 1Y
158.10
Interactive COPN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for COPN

Current P/E Ratio (ttm) 29.7448
Estimated P/E(12/2015) 130.0740
Relative P/E vs. SMI -
Earnings Per Share (EUR) (ttm) 5.0750
Est. EPS (EUR) (12/2015) 1.1600
Est. PEG Ratio -
Market Cap (M CHF) 2,273.87
Shares Outstanding (M) 14.42
30 Day Average Volume 17,459
Price/Book (mrq) 13.9783
Price/Sale (ttm) 27.2928
Dividend Indicated Gross Yield -%
Cash Dividend (EUR) -
Dividend Ex-Date 04/28/2015
5 Year Dividend Growth -
Next Earnings Announcement 07/30/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for COPN

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for COPN

Cosmo Pharmaceuticals SA develops and manufactures therapies for gastrointestinal diseases. The Company's proprietary technology delays the delivery of the active drug mainly into the lumen of the colon. Cosmo develops treatments for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, and for colon infections.

Mauro Severino AjaniChairman/FounderAlessandro Della ChaChief Executive Officer
Hans Christoph TannerCFO/Investor RelationsMarco LecchiDeputy Chief Financial Officer
More Company Profile & Key Executives for COPN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil